- About us
- About Vaccines
- Media centre
- EU initiatives
Vaccines Europe launched a Manifesto calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
Overall views about the strategy proposed by EMA’s Regulatory Science to 2025
EMA’s Regulatory science strategy to 2025 is highly welcomed by Vaccines Europe, a trade association representing the major innovative research-based vaccine companies as well as small and medium sized enterprises operating in Europe. It is generally accepted that vaccines designed to prevent infectious diseases are one of the most cost effective health care interventions. The World Health Organization estimates that existing vaccines prevent approximately 2–3 million deaths per year. Vaccines have also indirect economic and social benefits such as improved labour productivity and cognitive development, as well as averted treatment costs.
Today, close to 30 diseases are preventable by vaccination but there remain many unmet needs, for example:
Vaccines Europe is recruiting a Manager, Policy and Government Affairs who will report to Vaccines Europe Executive Director. This position provides a great opportunity to actively engage in the EU policy making process, with EU policy makers and other stakeholders, and to learn about the vaccines industry. Read more…
The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The 2019 Prize edition aims at rewarding significant achievements in Vaccines R&D in Europe.
The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of immune responses, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).
For information regarding application criteria, follow this link.
The World Health Organization (WHO) recommendations for the viruses to be included in influenza vaccines each season provide critical guidance to national public health authorities, regulatory agencies and vaccine manufacturers in advance of development and production.
During the 21st February 2019 meeting (Beijing, China), the WHO postponed the recommendation of the A (H3N2) strain candidate. One month later, on the 21st of March 2019, the WHO recommended the A(H3N2) vaccine strain for the Northern Hemisphere 2019-2020 season. This was an A/Kansas/14/2017 (H3N2)-like virus (see link for the WHO 2019-2020 strain recommendation).
In line with the published statement of the International Federation of Pharmaceutical Manufacturers & Associations, IFPMA (see link for the IFPMA statement), Vaccines Europe (VE) would also like to reiterate that protecting public health through annual seasonal influenza vaccination campaigns and achieving vaccination coverage goals are critical. Following the WHO’s recommendations, it takes approximately 6-8 months to produce and approve the full global supply of influenza vaccines. VE encourages National Health Authorities to continue preparing their influenza vaccination campaigns, mindful of potential changes to the campaign start and end dates, given the late WHO announcement on A/H2N3 strain candidate.
As a longstanding public health partner in the field, VE and its members are closely cooperating with European and National Regulatory Authorities to minimise any potential delays and provide a sustainable and timely supply of influenza vaccines for the 2019/20 season.